Last reviewed · How we verify
NCT04330937: CITROXI
Clinical Trial on the Effectiveness of Citrolive
NA trial testing dietetics in Cardiovascular Risk in 23 participants. Completed in 1 February 2020.
30 November 2019
Quick facts
| Lead sponsor | Universidad Católica San Antonio de Murcia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 23 |
| Start date | 1 October 2017 |
| Primary completion | 30 November 2019 |
| Estimated completion | 1 February 2020 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- dietetics
Conditions studied
- Cardiovascular Risk — all drugs for Cardiovascular Risk →
Sponsor
Universidad Católica San Antonio de Murcia
Who can join
Adults 18 to 65, any sex, with Cardiovascular Risk. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical trial consists in checking the antioxidant effect of citrolive on low density cholesterol.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effectiveness of Consumption of a Combination of Citrus Fruit Flavonoids and Olive Leaf Polyphenols to Reduce Oxidation of Low-Density Lipoprotein in Treatment-Naïve Cardiovascular Risk Subjects: A Randomized Double-Blind Controlled Study.
Victoria-Montesinos D, Abellán Ruiz MS, Luque Rubia AJ, Guillén Martínez D, et al · · 2021 · cited 6× · PMID 33920476 · DOI 10.3390/antiox10040589
Verify or expand the search:
- PubMed search for NCT04330937
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Risk
Currently open trials in the same condition.
- NCT06837181 — Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) · recruiting
- NCT06670677 — Evaluation of the Clinical Benefit of the Aktiia Blood Pressure Monitoring for Early Awareness of Hypertension and Predi · recruiting
- NCT06832644 — Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CV · NA · recruiting
- NCT06714058 — Cardiometabolic Risk of Obese Subjects: Cross-sectional Study · recruiting
- NCT06118281 — ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack · Phase 3 · recruiting
Other Universidad Católica San Antonio de Murcia trials
Trials by the same sponsor.
- NCT07397910 — Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection · NA · not yet recruiting
- NCT07519980 — Xanthigen and Its Impact on Weight and Metabolic Health · NA · recruiting
- NCT07391189 — Healthy Effects of Adapted Aikido in People With Grip Disfunction · NA · recruiting
- NCT07379931 — Evaluating a Liquid Extract of Carob to Improve Blood Sugar in People With Prediabetes · NA · not yet recruiting
- NCT07488000 — Plyometric Exercises During the Winter Pre-season in Sprinters · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04330937 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Católica San Antonio de Murcia
- Last refreshed: 2 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04330937.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing